Trevi Therapeutics Q1 2024 GAAP EPS $(0.11) Misses $(0.09) Estimate
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics reported Q1 2024 GAAP EPS of $(0.11), missing the $(0.09) estimate, marking an 83.33% increase in losses from the same period last year.
May 07, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Trevi Therapeutics reported a larger than expected quarterly loss of $(0.11) per share, missing the $(0.09) estimate and showing a significant increase in losses from the previous year.
The reported earnings miss and the significant increase in losses year-over-year are likely to negatively impact investor sentiment towards TRVI in the short term. Earnings misses often lead to downward pressure on a stock's price as they can signal operational or market challenges. The 83.33% increase in losses compared to the same period last year further exacerbates concerns, potentially leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100